US 11,939,312 B2
Enantiomeric entactogen compositions and their use
Nikita Obidin, Seattle, WA (US)
Assigned to Arcadia Medicine, Inc., San Francisco, CA (US)
Filed by Arcadia Medicine, Inc., San Francisco, CA (US)
Filed on Aug. 3, 2023, as Appl. No. 18/230,142.
Application 18/230,142 is a continuation of application No. PCT/US2022/032275, filed on Jun. 3, 2022.
Claims priority of provisional application 63/196,226, filed on Jun. 3, 2021.
Prior Publication US 2023/0382885 A1, Nov. 30, 2023
Int. Cl. C07D 317/58 (2006.01); A61K 9/00 (2006.01); A61P 25/22 (2006.01)
CPC C07D 317/58 (2013.01) [A61K 9/0053 (2013.01); A61P 25/22 (2018.01)] 30 Claims
 
1. A non-racemic mixture comprising R(−)-3,4-methylenedioxymethamphetamine (R-MDMA) or a pharmaceutically acceptable salt thereof, and S(+)-3,4-methylenedioxymethamphetamine (S-MDMA) or a pharmaceutically acceptable salt thereof, in a molar ratio of R-MDMA to S-MDMA of 9:1.